Multifactor Risk Reduction for Optimal Management of PAD
VIGOR2
1 other identifier
interventional
300
0 countries
N/A
Brief Summary
Patients with peripheral arterial disease (PAD) experience significant functional limitations due to ischemic symptoms (claudication) and are at high risk for CVD morbidity and mortality resulting from untreated cardiovascular disease (CVD) risk factors and aggressive atherosclerosis. The overall Goal of this randomized controlled clinical trial is to examine the synergistic effect of a multifactor risk reduction on walking distance, blood flow and quality of life in 300 patients with PAD. Specifically, we will compare the effects of 24 months of a novel, yet well-tested multiple risk factor reduction program, the Health Education and Risk Reduction Training (HEAR2T) Program for PAD versus enhanced standard care on: 1) symptom limited walking distance as assessed by treadmill exercise testing and walking impairment questionnaire; 2) endothelial function as measured by flow mediated vasodilation (FMVD) via brachial artery ultrasound. We will also explore the association between FMVD and decreased oxidative stress (as measured by oxygen radical absorbance capacity and urinary isoprostanes) and reduced degradation of nitric oxide (NO) and/or increased NO biosynthesis (as measured by urine nitrogen oxide, plasma nitrogen oxide, plasma asymmetric dimethylarginine, plasma, urine and platelet cyclic GMP). Secondary hypotheses examine the association between reducing CVD risk factors, improved endothelial function, increased walking distance, improved quality of life and number of metabolic syndrome abnormalities in PAD patients. Significance. This study will contribute to evidence on the efficacy of multiple risk factor reduction on improving physical function and quality of life in the understudied, elderly PAD patient. This study will also provide preliminary evidence for the biological basis for the efficacy of multifactor risk reduction in restoring vascular homeostasis, critical because of its role in antiatherogenesis and maintaining vasoreactivity, both necessary for slowing the progression of atherosclerosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2006
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2006
CompletedFirst Submitted
Initial submission to the registry
September 27, 2007
CompletedFirst Posted
Study publicly available on registry
October 1, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2013
CompletedApril 19, 2023
April 1, 2023
6.8 years
September 27, 2007
April 17, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
walking time
determined by symptom limited walking time on treadmill exercise test
24 months
Secondary Outcomes (1)
quality of life, biomarkers of CVD risk, endothelial function
24 months
Study Arms (2)
A-Exercise group
EXPERIMENTALHome based exercise
B- Usual Care
NO INTERVENTIONExercise as usually prescribed by provider
Interventions
Eligibility Criteria
You may qualify if:
- Subjects eligible for this study include:
- Age 50 years or older with one or more CVD risk factor
- PAD secondary to atherosclerosis with significant claudication
- Claudication is defined as pain, ache, cramp, numbness or severe fatigue of muscles of one or both lower extremities, reproducibly provoked by walking causing the patient to slow or stop walking pace
- Ankle-brachial index (ABI) \< 0.90
- In diabetics ABI is inaccurate, in which case, we will substitute toe pressures \< 60 mmHg
- ABI one minute after exercise is at least 20% lower than index leg resting ABI
- Capable of walking at least 50 feet
- Primary limitation to walking is claudication, not coexisting conditions such as severe CAD, uncontrolled hypertension, pulmonary disease, severe arthritis, or orthopedic conditions
- Difference of walking time between two consecutive (of four) baseline treadmill tests must be \< 25%.
You may not qualify if:
- Active malignancy or tumor or other condition that would severely limit life expectancy
- Any type of major surgery during the last 3 months (i.e. aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy, leg amputation above the ankle)
- Residence in a long-term institutional setting
- Psychiatric disorders with currently active manifestations
- Uncontrolled metabolic disorders (renal failure, liver failure, thyrotoxicosis)
- Active symptoms suggestive of an acute coronary syndrome or decompensated heart failure
- Lack of phone access (either by self or through neighbors/family members)
- Other specified circumstances incompatible with case-management (i.e., plan to move away from area)
- Presence of another household member or first-degree relative already enrolled in the study
- Current enrollment in another clinical trial
- Regular participation in an exercise program for at least 3 months prior to study entry.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Palo Alto Veterans Institute for Researchlead
- Stanford Universitycollaborator
- University of California, San Franciscocollaborator
Related Publications (2)
Oka RK, Conte MS, Owens CD, Rapp J, Fung G, Alley HF, Giacomini JC, Myers J, Mohler ER 3rd. Efficacy of optimal long-term management of multiple cardiovascular risk factors (CVD) on walking and quality of life in patients with peripheral artery disease (PAD): protocol for randomized controlled trial. Vasc Med. 2012 Feb;17(1):17-28. doi: 10.1177/1358863X11430886.
PMID: 22363015BACKGROUNDOka RK, Alley HF. Differences in nutrition status by body mass index in patients with peripheral artery disease. J Vasc Nurs. 2012 Sep;30(3):77-87. doi: 10.1016/j.jvn.2012.04.003.
PMID: 22901446RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Roberta K Oka, ANP, DNSc
PAIRE
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 27, 2007
First Posted
October 1, 2007
Study Start
September 1, 2006
Primary Completion
June 1, 2013
Study Completion
June 1, 2013
Last Updated
April 19, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share